High-Dose Maternal Tamoxifen Induces Developmental Malformat
2026-05-30
This study demonstrates that a single high dose of tamoxifen in pregnant mice can cause dose-dependent craniofacial and limb malformations in offspring. The findings underscore the importance of dose selection and timing when using tamoxifen in developmental and genetic studies.
FLOT1–FOSL2–EphA2 Axis Regulates Microglial Polarization in
2026-05-29
This study identifies the FLOT1–FOSL2 interaction as a key regulator of EphA2 transcription, which drives pro-inflammatory microglial polarization and neuroinflammation in Alzheimer's disease. By elucidating this signaling axis, the research provides mechanistic insight into microglial dynamics and highlights new intervention points for modulating cognitive decline.
Sodium Overload Disrupts Mitochondrial Metabolism in NECSO C
2026-05-29
The recent work by Qiao et al. reveals that sodium influx through TRPM4 channels disrupts mitochondrial energy metabolism, directly triggering necrosis by sodium overload (NECSO). Their mechanistic insights clarify how mitochondrial depolarization and energy failure underlie sodium-driven cell death, with implications for research on ischemia, organ failure, and ion homeostasis.
Phebestin as a Potent Aminopeptidase Inhibitor Against Malar
2026-05-28
This study demonstrates that phebestin, a bestatin-related aminopeptidase inhibitor, exhibits nanomolar efficacy against both chloroquine-sensitive and resistant Plasmodium falciparum strains with low cytotoxicity. The findings highlight phebestin's mechanistically distinct antimalarial potential and inform future therapeutic strategies targeting parasite-specific peptidases.
Early Life Adversity Disrupts Innate Defense via Oxytocin Lo
2026-05-28
Tan et al. reveal that early life adversity (ELA), modeled by postnatal social deprivation in mice, leads to impaired visually evoked innate defensive responses through reduced oxytocin signaling in the superior colliculus. This mechanistic insight advances understanding of how ELA shapes neural circuits relevant to fear processing and highlights molecular targets for future intervention.
Trifluoperazine 2HCl: Enhancing Dopaminergic Assays in Resea
2026-05-27
This article provides a scenario-driven guide for biomedical researchers seeking reliable solutions for dopaminergic signaling pathway studies using Trifluoperazine 2HCl (SKU B1397). It addresses real laboratory challenges—ranging from reproducibility in cell viability assays to product selection criteria—while emphasizing protocol optimization and validated data. Researchers will gain actionable insights for achieving robust, interpretable results in neuropharmacology and cancer biology workflows.
Anagliptin (SK-0403): Precision DPP-4 Inhibition for Vascula
2026-05-27
Anagliptin (SK-0403) propels diabetes and vascular research beyond glycemic control, uniquely enabling combined DPP-4 inhibition and direct vascular modulation. This article details experimental workflows, protocol parameters, and troubleshooting strategies rooted in the latest mechanistic insights—empowering researchers to interrogate Kv channel and SERCA pump activity with confidence.
Electrostatic Partitioning and Precision: Cy5 Maleimide in A
2026-05-26
Explore how Cy5 maleimide (non-sulfonated) enables next-generation, electrostatically informed protein labeling for demanding fluorescence applications. This article reveals practical assay strategies and interprets cutting-edge research on molecular partitioning, going beyond standard protocol guidance.
Mitoxantrone HCl: DNA Topoisomerase II Inhibitor in Oncology
2026-05-26
Mitoxantrone HCl stands out as a DNA topoisomerase II inhibitor with dual roles in DNA damage and nuclear receptor modulation, opening new avenues for resistance-overcoming cancer research. Its versatility spans leukemia, multiple sclerosis, and apoptosis induction in stem cells, with recent studies highlighting its unique allosteric targeting of ERα.
Protein A/G Magnetic Co-IP/IP Kit: Optimizing Co-IP Workflow
2026-05-26
The Protein A/G Magnetic Co-IP/IP Kit empowers researchers to dissect protein-protein interactions with unparalleled specificity and efficiency using recombinant Protein A/G magnetic beads. Its streamlined workflow and robust Fc region antibody binding support advanced applications from stem cell signaling to high-fidelity proteomics.
Oleanolic Acid in Dual-Loaded Liposomes: Mechanistic Advance
2026-05-25
Explore the advanced mechanistic role of oleanolic acid in dual-loaded liposome research, focusing on inducible nitric oxide synthase induction and innovative encapsulation efficiency methodologies. This in-depth analysis uniquely connects mechanistic understanding with practical, assay-level decisions.
BicD and MAP7 Synergistically Activate Drosophila Kinesin-1
2026-05-24
This study reveals how the adaptor protein BicD and microtubule-associated protein MAP7 independently and cooperatively activate Drosophila kinesin-1 by distinct mechanisms. These findings clarify the regulatory interplay between adaptors and microtubule-associated proteins in controlling motor processivity, with implications for bidirectional cargo transport.
Talabostat Mesylate (PT-100): Workflow Optimization in Cance
2026-05-23
Talabostat mesylate (PT-100) stands out as both a specific DPP4 and FAP inhibitor, enabling advanced modulation of the tumor microenvironment. This article navigates optimized experimental workflows, troubleshooting, and the translational impact of PT-100, guided by breakthrough findings on pericyte-targeted therapy and robust protocol design.
Rapakinin-Induced Vasorelaxation via PGI2–IP and CCK1 Recept
2026-05-22
This study characterizes the anti-hypertensive peptide rapakinin, derived from rapeseed protein, which induces vasorelaxation in mesenteric arteries of spontaneously hypertensive rats by a prostaglandin I2 IP receptor- and CCK1 receptor-dependent mechanism. The findings clarify a non-canonical pathway for vascular relaxation, distinct from classical ACE inhibition, with implications for peptide-based cardiovascular research.
Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera
2026-05-22
This study details the development of new allosteric inhibitors targeting pyruvate dehydrogenase kinase 4 (PDK4), a key regulator in glucose metabolism and metabolic diseases. The lead compound, 8c, demonstrates potent activity, favorable metabolic stability, and efficacy in preclinical models of hyperglycemia, allergy, and cancer, offering a promising scaffold for future drug development.
460 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page